The landscape of clinical artificial intelligence is currently characterized by a dual narrative: immense potential for transforming patient care alongside significant challenges related to safety, equity, and governance. AI-driven clinical decision support systems (CDS) are increasingly recognized for their capacity to enhance diagnostics, personalize treatment recommendations, predict risks, and optimize medication safety, as detailed in reviews exploring their impact on preventing adverse events and supporting cost-effective prescribing. However, the efficacy and safety of these systems are contingent upon addressing critical issues such as interpretability, algorithmic bias, data privacy, and the need for high-quality, representative training data. Regulatory frameworks are rapidly evolving to keep pace with technological advancements. The FDA continues to be a primary regulator, overseeing AI/ML-enabled software as a medical device (SaMD) through established premarket clearance and approval pathways. Recent draft guidance from the FDA, such as the January 2025 recommendations on lifecycle management and marketing submissions, introduces expectations for performance monitoring, documentation of model inputs and outputs, and Predetermined Change Control Plans for adaptive AI systems. This risk-based approach aims to ensure safety and effectiveness throughout the AI product lifecycle, as further analyzed in a JAMA perspective on FDA oversight and clinical standards. Despite these regulatory efforts, concerns persist regarding the speed of AI adoption versus the rigor of safety checks. A report in PLOS Digital Health, highlighted by Nature, warns that hospitals are rapidly deploying AI tools for diagnosis, triage, and documentation, yet regulatory oversight has not kept pace. Experts advocate for continuous post-deployment monitoring and stronger institutional governance, emphasizing that current FDA pathways for medical AI may be less rigorous than those for pharmaceuticals. This underscores the critical need for healthcare organizations to implement robust internal governance frameworks, aligning with recommendations from The Joint Commission–Coalition for Health AI and emerging state laws requiring clinician oversight and patient disclosure. Algorithmic bias and data quality remain central to achieving equitable AI outcomes. Articles consistently stress that poorly curated datasets can exacerbate racial and ethnic disparities, while inclusive data and active bias mitigation strategies are essential for equitable care. The Journal of Medical Internet Research identifies transparency, usability, clinical reliability, and ethical considerations like fairness as key themes influencing healthcare workers' trust in AI-based CDS. Opaque algorithms and inadequate training can erode this trust, indirectly compromising patient safety and equity. Patient safety and ethical considerations are particularly acute in the realm of mental health AI. Multiple sources, including PBS NewsHour and analyses from the National Academy of Medicine and the American Psychological Association, express significant caution regarding the use of AI chatbots for therapy or health advice. These tools often lack access to personal medical history, can provide hallucinated or unsafe recommendations, and are not clinically validated. Psychologists report concerns that chatbots may reinforce negative behaviors or blur the line between self-help and clinical care, highlighting the urgent need for clear guidance on how AI companions should be integrated—or kept separate—from formal mental health treatment. From the LOG Standards perspective, the current environment demands a proactive and comprehensive approach to AI governance. The increasing number of FDA-authorized AI-enabled medical devices, exceeding 1,400 by March 2026, necessitates stringent adherence to evolving regulatory guidance and the establishment of robust, transparent validation and certification processes. The emphasis on high-quality, representative data, rigorous bias mitigation, and continuous post-market surveillance is paramount. Furthermore, as organizations like NEJM launch dedicated AI journals and nurses increasingly utilize AI for administrative tasks, it is critical that all clinical AI applications are developed and deployed with explicit patient safety goals, comprehensive clinician training, and a commitment to ethical principles and workforce readiness, as advocated by European digital health advisory groups.
